Alterity Therapeutics ( (AU:ATH) ) just unveiled an announcement.
Alterity Therapeutics announced that the U.S. FDA has granted Fast Track designation for its lead candidate, ATH434, aimed at treating Multiple System Atrophy (MSA). This designation is expected to accelerate the development and review process of ATH434, highlighting its potential to meet the high unmet need for MSA treatments. The Fast Track status allows Alterity to engage more frequently with the FDA, potentially speeding up the path to approval. The company has demonstrated ATH434’s efficacy and safety in Phase 2 trials, showing significant improvements in clinical outcomes for MSA patients.
More about Alterity Therapeutics
Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases. The company is working on innovative therapies to address unmet medical needs, particularly in conditions like Multiple System Atrophy (MSA), where no approved treatments currently exist.
Average Trading Volume: 1,000
Technical Sentiment Signal: Buy
Current Market Cap: $52.95M
Find detailed analytics on ATH stock on TipRanks’ Stock Analysis page.